<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="280b9843-9353-465b-9b94-c0d67b1e6fd6"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use TZIELD safely and effectively. See full prescribing information for TZIELD.<br/>
      <br/> TZIELD<sup>®</sup> (teplizumab-mzwv) injection, for intravenous use<br/> Initial U.S. Approval: 2022</title>
   <effectiveTime value="20250506"/>
   <setId root="e8a39a5f-139c-4510-9777-71cbb00138fa"/>
   <versionNumber value="5"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="080768105" root="1.3.6.1.4.1.519.1"/>
            <name>Provention Bio, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="824771724" root="1.3.6.1.4.1.519.1"/>
                        <name>AGC Biologics, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="73650-316" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="023050730" root="1.3.6.1.4.1.519.1"/>
                        <name>Ajinomoto Althea, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="73650-316" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="078607239" root="1.3.6.1.4.1.519.1"/>
                        <name>Almac Pharma Services LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="73650-316" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="73650-316" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="3f2e8b68-9bd2-48b6-b8b9-7493f907dcb1"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20250430"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="73650-316" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>TZIELD</name>
                        <formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>teplizumab-mzwv</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="1" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="S4M959U2IJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TEPLIZUMAB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="S4M959U2IJ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TEPLIZUMAB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="0.26" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="E1W4N241FO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM PHOSPHATE, DIBASIC, DODECAHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="1.13" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="5QWK665956" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="8.78" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="0.05" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="2" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="73650-316-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20221117"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TYPE 0: NOT A COMBINATION PRODUCT" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="2" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="10" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="73650-316-10" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20221117"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TYPE 0: NOT A COMBINATION PRODUCT" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="2" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="14" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="73650-316-14" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20221117"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TYPE 0: NOT A COMBINATION PRODUCT" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761183" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20221117"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="s1">
               <id root="81a6ca0f-a70a-4a90-a697-0ae70786713f"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>TZIELD is indicated to delay the onset of Stage 3 type 1 diabetes in adults and pediatric patients 8 years of age and older with Stage 2 type 1 diabetes <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s2.1">2.1</linkHtml>)]</content>.</paragraph>
               </text>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>TZIELD is a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D (<linkHtml href="#s1">1</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s2">
               <id root="f9321f4d-956c-477a-9e98-a4577b31396e"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Confirm Stage 2 T1D by documenting at least two positive pancreatic islet autoantibodies in those who have dysglycemia without overt hyperglycemia using an oral glucose tolerance test (OGTT) or alternative method if appropriate and OGTT is not available (<linkHtml href="#s2.1">2.1</linkHtml>).</item>
                           <item>In patients who meet criteria for a diagnosis of Stage 2 type 1 diabetes, ensure the clinical history of the patient does not suggest type 2 diabetes (<linkHtml href="#s2.1">2.1</linkHtml>).</item>
                           <item>Prior to initiating TZIELD, obtain a complete blood count and liver enzyme tests. Use of TZIELD is not recommended in patients with certain laboratory abnormalities (<linkHtml href="#s2.2">2.2</linkHtml>).</item>
                           <item>Must dilute TZIELD in 0.9% Sodium Chloride Injection, USP. See full prescribing information for detailed preparation and administration instructions (<linkHtml href="#s2.3">2.3</linkHtml>, <linkHtml href="#s2.4">2.4</linkHtml>, <linkHtml href="#s2.5">2.5</linkHtml>).</item>
                           <item>Premedicate with: (1) a nonsteroidal anti-inflammatory drug (NSAID) or acetaminophen, (2) an antihistamine, and/or (3) an antiemetic before each TZIELD dose for at least the first 5 days of the 14-day treatment course (<linkHtml href="#s2.3">2.3</linkHtml>).</item>
                           <item>Administer TZIELD by intravenous infusion (over a minimum of 30 minutes) once daily for 14 days. See full prescribing information for the dosing schedule (<linkHtml href="#s2.4">2.4</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s2.1">
                     <id root="3f0bdb76-6725-4786-83c2-57ccb8c5400b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Patient Selection</title>
                     <text>
                        <paragraph>Select adult patients and pediatric patients 8 years of age and older for TZIELD treatment who have a diagnosis of Stage 2 type 1 diabetes. <br/>
                           <br/>
                        </paragraph>
                        <list listType="unordered">
                           <item>Confirm Stage 2 type 1 diabetes by documenting:<list listType="unordered">
                                 <item>At least two positive pancreatic islet cell autoantibodies</item>
                                 <item>Dysglycemia without overt hyperglycemia using an oral glucose tolerance test (if an oral glucose tolerance test is not available, an alternative method for diagnosing dysglycemia without overt hyperglycemia may be appropriate)</item>
                              </list>
                           </item>
                           <item>Ensure the clinical history of the patient does not suggest type 2 diabetes.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="s2.2">
                     <id root="e14c67f4-319b-4d7c-bf56-109928f31e59"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Laboratory Evaluation and Vaccination Prior to Initiation</title>
                     <text>
                        <br/>
                        <list listType="unordered">
                           <item>Prior to initiating TZIELD, obtain a complete blood count and liver enzyme tests.</item>
                           <item>Use of TZIELD is not recommended in patients with <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s5">5</linkHtml>)]</content>:<list listType="unordered">
                                 <item>Lymphocyte count less than 1,000 lymphocytes/mcL</item>
                                 <item>Hemoglobin less than 10 g/dL</item>
                                 <item>Platelet count less than 150,000 platelets/mcL</item>
                                 <item>Absolute neutrophil count less than 1,500 neutrophils/mcL</item>
                                 <item>Elevated ALT or AST greater than 2 times the upper limit of normal (ULN) or bilirubin greater than 1.5 times ULN</item>
                                 <item>Laboratory or clinical evidence of acute infection with Epstein-Barr virus (EBV) or cytomegalovirus (CMV)</item>
                                 <item>Active serious infection or chronic active infection other than localized skin infections</item>
                              </list>
                           </item>
                           <item>Administer all age-appropriate vaccinations prior to starting TZIELD <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s5.5">5.5</linkHtml>)]</content>:<list listType="unordered">
                                 <item>Administer live-attenuated (live) vaccines at least 8 weeks prior to treatment.</item>
                                 <item>Administer inactivated (killed) vaccines or mRNA vaccines at least 2 weeks prior to treatment.</item>
                              </list>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="s2.3">
                     <id root="737a5583-5f48-4189-b75e-f87f750cf31c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Important Preparation and Premedication Instructions</title>
                     <text>
                        <paragraph>The following are important preparation and premedication instructions:</paragraph>
                        <list listType="unordered">
                           <item>Must dilute TZIELD prior to use <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s2.5">2.5</linkHtml>)]</content>.</item>
                           <item>Premedicate prior to TZIELD infusion for the first 5 days of dosing with: (1) a nonsteroidal anti-inflammatory drug (NSAID) or acetaminophen, (2) an antihistamine, and/or (3) an antiemetic <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s5.1">5.1</linkHtml>)]</content>. Administer additional doses of premedication if needed.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="s2.4">
                     <id root="7aa999e3-5251-4c8b-9c81-d7c85790556b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Recommended Dosage and Administration</title>
                     <text>
                        <paragraph>Administer TZIELD by intravenous infusion (over a minimum of 30 minutes), using a body surface area-based dosing, once daily for 14 consecutive days as follows:</paragraph>
                        <list listType="unordered">
                           <item>Day 1: 65 mcg/m<sup>2</sup>
                           </item>
                           <item>Day 2: 125 mcg/m<sup>2</sup>
                           </item>
                           <item>Day 3: 250 mcg/m<sup>2</sup>
                           </item>
                           <item>Day 4: 500 mcg/m<sup>2</sup>
                           </item>
                           <item>Days 5 through 14: 1,030 mcg/m<sup>2</sup>
                           </item>
                        </list>
                        <paragraph>Do not administer two doses on the same day.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Recommendations Regarding Missed Dose(s)</content>
                           <br/>  If a planned TZIELD infusion is missed, resume dosing by administering all remaining doses on consecutive days to complete the 14-day treatment course.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="s2.5">
                     <id root="857ee84f-8a68-4729-a6af-23657b8ce5d9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Additional Preparation and Administration Instructions</title>
                     <text>
                        <paragraph>The following are additional preparation and administration instructions <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s2.2">2.2</linkHtml>, <linkHtml href="#s2.3">2.3</linkHtml>, <linkHtml href="#s2.4">2.4</linkHtml>)]</content>: <br/>
                           <br/>
                        </paragraph>
                        <list listType="unordered">
                           <item>Inspect TZIELD visually before use (the supplied solution is clear and colorless). Do not use TZIELD if particulate matter or coloration is seen.</item>
                           <item>Prepare TZIELD using aseptic technique. Each vial is intended for single dose only.</item>
                           <item>Prepare a:<list listType="unordered">
                                 <item>Sterile glass vial with 18 mL of 0.9% Sodium Chloride Injection <content styleCode="bold">
                                       <content styleCode="underline">or</content>
                                    </content>
                                 </item>
                                 <item>Polyvinylchloride (PVC) infusion bag with 18 mL of 0.9% Sodium Chloride Injection.</item>
                              </list>
                           </item>
                           <item>Remove 2 mL of TZIELD from the vial and slowly add to the 18 mL of 0.9% Sodium Chloride Injection. Mix gently by slowly inverting the vial or rocking the infusion bag. The resulting 20 mL diluted solution contains 100 mcg/mL of teplizumab-mzwv.</item>
                           <item>Using an appropriately sized syringe (e.g., 5 mL), withdraw the volume of diluted TZIELD solution required for that day's calculated dose from the 100 mcg/mL solution.</item>
                           <item>Slowly add contents of the syringe containing the TZIELD dose to a 25 mL 0.9% Sodium Chloride Injection PVC infusion bag. Gently rock the infusion bag to ensure that the solution mixes sufficiently. Do not shake.</item>
                           <item>Discard unused portion of remaining diluted TZIELD solution in the sterile glass vial or PVC infusion bag.</item>
                           <item>Start the TZIELD infusion within 2 hours of preparation. If not used immediately, store the infusion solution at room temperature [15°C to 30°C (59°F to 86°F)] and complete infusion within 4 hours of the start of preparation. Discard the infusion solution if not administered within 4 hours of preparation.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s3">
               <id root="3618e573-5b8d-4005-a006-3ab73ff6f52b"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Injection: 2 mg per 2 mL (1 mg/mL) clear and colorless solution in a single-dose vial.</paragraph>
               </text>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Injection: 2 mg per 2 mL (1 mg/mL) single-dose vial (<linkHtml href="#s3">3</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s4">
               <id root="4a6bb1fd-df06-4054-9344-f2135026aa52"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>None. (<linkHtml href="#s4">4</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s5">
               <id root="ace2c23e-7c07-4ddc-9204-8db682daa0ac"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <content styleCode="italics">Cytokine Release Syndrome (CRS):</content> Premedicate, monitor liver enzymes, discontinue in those that develop elevated ALT or AST more than 5 times the upper limit of normal, and if severe CRS develops consider temporarily pausing dosing (<linkHtml href="#s5.1">5.1</linkHtml>).</item>
                           <item>
                              <content styleCode="italics">Serious Infections:</content> Use of TZIELD is not recommended in patients with active serious infection or chronic infection. Monitor for signs and symptoms of infection during and after TZIELD treatment. If a serious infection develops, discontinue TZIELD (<linkHtml href="#s5.2">5.2</linkHtml>).</item>
                           <item>
                              <content styleCode="italics">Lymphopenia:</content> Monitor white blood cell counts during the treatment period. If prolonged severe lymphopenia (&lt;500 cells per mcL lasting 1 week or longer) develops, discontinue TZIELD (<linkHtml href="#s5.3">5.3</linkHtml>).</item>
                           <item>
                              <content styleCode="italics">Hypersensitivity Reactions:</content> If severe hypersensitivity reactions occur, discontinue TZIELD and treat promptly (<linkHtml href="#s5.4">5.4</linkHtml>).</item>
                           <item>
                              <content styleCode="italics">Vaccinations:</content> Administer all age-appropriate vaccinations prior to starting TZIELD. See recommendations regarding live-attenuated, inactivated, and mRNA vaccines (<linkHtml href="#s2.2">2.2</linkHtml>, <linkHtml href="#s5.5">5.5</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s5.1">
                     <id root="f45230b4-e592-4e38-aec2-831a2e5d70bd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Cytokine Release Syndrome</title>
                     <text>
                        <paragraph>Cytokine release syndrome (CRS) has been observed in TZIELD-treated patients. In clinical trials, CRS was reported in 5% of TZIELD-treated patients compared to 0.8% of control-treated patients during the treatment period and through 28 days after the last study drug administration. CRS manifestations in TZIELD-treated patients included fever, nausea, fatigue, headache, myalgia, arthralgia, increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), and increased total bilirubin. These manifestations typically occurred during the first 5 days of TZIELD treatment <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s6.1">6.1</linkHtml>)]</content>. To mitigate CRS: <br/>
                           <br/>
                        </paragraph>
                        <list listType="unordered">
                           <item>Premedicate with antipyretics, antihistamines and/or antiemetics prior to TZIELD treatment <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s2.3">2.3</linkHtml>)]</content>.</item>
                           <item>Monitor liver enzymes during treatment. Discontinue TZIELD treatment in patients who develop elevated ALT or AST more than 5 times the upper limit of normal (ULN) or bilirubin more than 3 times ULN.</item>
                           <item>Treat symptoms of CRS with antipyretics, antihistamines and/or antiemetics. If severe CRS develops, consider temporarily pausing dosing for 1-2 days (and administer the remaining doses to complete the full 14-day course on consecutive days) or discontinuing treatment.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="s5.2">
                     <id root="535111b8-099e-481d-86cb-b3a774b21f80"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Serious Infections</title>
                     <text>
                        <paragraph>Bacterial and viral infections have occurred in TZIELD-treated patients. In clinical trials, TZIELD-treated patients had a higher rate of serious infections (3.5%) than control-treated patients (2%), including gastroenteritis, cellulitis, pneumonia, abscess, sepsis <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s6.1">6.1</linkHtml>)]</content>. Use of TZIELD is not recommended in patients with active serious infection or chronic infection other than localized skin infections. Monitor patients for signs and symptoms of infection during and after TZIELD treatment. If serious infection develops, treat appropriately, and discontinue TZIELD.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="s5.3">
                     <id root="d554b918-a25f-4563-a5c4-3902661ffa10"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Lymphopenia</title>
                     <text>
                        <paragraph>In clinical trials, 78% of TZIELD-treated patients developed lymphopenia compared to 11% of control-treated patients. For most TZIELD-treated patients who experienced lymphopenia, lymphocyte levels began to recover after the fifth day of treatment and returned to pre-treatment values within two weeks after treatment completion and without dose interruption. Severe lymphopenia (&lt;500 cells per mcL) lasting 1 week or longer occurred in 0.9% of TZIELD-treated patients, and 0.5% of TZIELD-treated patients permanently discontinued TZIELD because of lymphopenia <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s6.1">6.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>Monitor white blood cell counts during the treatment period. If prolonged severe lymphopenia (&lt;500 cells per mcL lasting 1 week or longer) develops, discontinue TZIELD.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="s5.4">
                     <id root="597be42a-b258-47ec-b8c7-d017a4bae62f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Hypersensitivity Reactions</title>
                     <text>
                        <paragraph>Acute hypersensitivity reactions including serum sickness, angioedema, urticaria, rash, vomiting and bronchospasm occurred in TZIELD-treated patients <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s6.1">6.1</linkHtml>)]</content>. If severe hypersensitivity reactions occur, discontinue use of TZIELD and treat promptly.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="s5.5">
                     <id root="c8b24440-ce9c-4cf3-ab6c-e734a31e3fa7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Vaccinations</title>
                     <text>
                        <paragraph>The safety of immunization with live-attenuated vaccines in TZIELD-treated patients has not been studied. Additionally, TZIELD may interfere with the immune response to vaccination and decrease vaccine efficacy. <br/>
                           <br/>
                        </paragraph>
                        <list listType="unordered">
                           <item>Administer all age-appropriate vaccinations prior to starting TZIELD <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s2.2">2.2</linkHtml>)]</content>.</item>
                           <item>Inactivated or mRNA vaccinations are not recommended within the 2 weeks prior to TZIELD treatment, during treatment, or 6 weeks after completion of treatment.</item>
                           <item>Live-attenuated vaccinations are not recommended within the 8 weeks prior to TZIELD treatment, during treatment, or up to 52 weeks after treatment.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s6">
               <id root="7f0fe0ac-bb4b-4bed-abee-1505b079e817"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following serious adverse reactions are described elsewhere in the Prescribing Information: <br/>
                     <br/>
                  </paragraph>
                  <list listType="unordered">
                     <item>Cytokine Release Syndrome <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s5.1">5.1</linkHtml>)]</content>
                     </item>
                     <item>Serious Infections <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s5.2">5.2</linkHtml>)]</content>
                     </item>
                     <item>Lymphopenia <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s5.3">5.3</linkHtml>)]</content>
                     </item>
                     <item>Hypersensitivity Reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s5.4">5.4</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (&gt;10%) were lymphopenia, rash, leukopenia and headache (<linkHtml href="#s6.1">6.1</linkHtml>).</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Provention Bio at 1-800-633-1610 or FDA at 1-800-FDA-1088 or <content styleCode="bold">
                                 <linkHtml href="#_Ref">www.fda.gov/medwatch</linkHtml>
                              </content>
                           </content>
                        </paragraph>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s6.1">
                     <id root="c4c38d4a-24c1-4af3-8a53-eeb61b379a64"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Placebo-Controlled Study in Patients with Stage 2 Type 1 Diabetes</content>
                           <br/>  The data in Table 1 are derived from the placebo-controlled study (Study TN-10) in patients aged 8 years and older with Stage 2 type 1 diabetes (T1D) <content styleCode="italics">[see Clinical Studies (<linkHtml href="#s14">14</linkHtml>)]</content>. These data reflect exposure of 44 patients of whom 93% completed the full 14-day treatment course.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Pool of Five Controlled Clinical Studies in Stage 2 Type 1 Diabetes and in an Unapproved Population</content>
                           <br/>  Adverse reactions in TZIELD-treated patients were also evaluated in a larger pool of adult and pediatric patients who participated in five controlled clinical studies (including Study TN-10 described above): <br/>
                           <br/>
                        </paragraph>
                        <list listType="unordered">
                           <item>One study in patients with Stage 2 T1D (Study TN-10) <content styleCode="italics">[see Clinical Studies (<linkHtml href="#s14">14</linkHtml>)]</content>,</item>
                           <item>Three placebo-controlled studies in an unapproved population,</item>
                           <item>One open-label standard-of-care controlled study of TZIELD in an unapproved population.</item>
                        </list>
                        <paragraph>In this pool: <br/>
                           <br/>
                        </paragraph>
                        <list listType="unordered">
                           <item>773 patients received TZIELD (44 patients with Stage 2 TID and 729 patients from an unapproved population), and</item>
                           <item>245 patients received either placebo or standard of care control (32 patients with Stage 2 T1D and 213 patients from an unapproved population).</item>
                        </list>
                        <paragraph>In these studies, 436 patients received a 14-day dosing regimen of TZIELD with a total drug exposure that was comparable to the total drug exposure achieved with the recommended dosage <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s2.4">2.4</linkHtml>)]</content>, 168 patients received a 14-day course of TZIELD with a lower total TZIELD drug exposure, and 169 patients received a 6-day course of TZIELD with a lower total TZIELD drug exposure. The mean age of TZIELD-treated patients was 17.6 years (median 15 years), 62% were &lt;18 years old (40% age 12 to 17; 21% age 8 to 11), and 64% were male. The population was 72% White, 26% Asian, 1% Black or African American, 1% were multiple or unknown race, and &lt;1% American Indian or Alaska Native; 5% were Hispanic or Latino ethnicity.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Common Adverse Reactions</content>
                           <br/>
                           <linkHtml href="#t1">Table 1</linkHtml> presents common (≥ 5%) adverse reactions that occurred during treatment and through 28 days after the last study drug administration in Study TN-10. Adverse reactions observed in pediatric patients 8 years and older who received TZIELD were consistent with those reported in adult patients in this study.</paragraph>
                        <table width="95%" ID="t1">
                           <caption>Table 1. Common Adverse Reactions<footnote ID="table_1_footnote1">That occurred during treatment and through 28 days after the last study drug administration</footnote> in Adult and Pediatric Patients Aged 8 Years and Older with Stage 2 Type 1 Diabetes (Study TN-10)<footnote ID="table_1_footnote2">Adverse reactions that occurred in 2 or more TZIELD-treated patients</footnote>
                           </caption>
                           <col width="40%" align="left" valign="middle"/>
                           <col width="30%" align="center" valign="middle"/>
                           <col width="30%" align="center" valign="middle"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Botrule " valign="top">Adverse Reaction</th>
                                 <th styleCode="Lrule Botrule">Placebo <br/>  N=32</th>
                                 <th styleCode="Lrule Botrule Rrule">TZIELD <br/>  N=44</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Botrule">Lymphopenia</td>
                                 <td styleCode="Lrule Botrule">6%</td>
                                 <td styleCode="Lrule Botrule Rrule">73%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule">Rash<footnote ID="table_1_footnote3">Composite of rash-related terms including rash erythematous, rash macular, rash papular, rash maculo-papular, rash pruritic</footnote>
                                 </td>
                                 <td styleCode="Lrule Botrule">0%</td>
                                 <td styleCode="Lrule Botrule Rrule">36%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule">Leukopenia</td>
                                 <td styleCode="Lrule Botrule">0%</td>
                                 <td styleCode="Lrule Botrule Rrule">21%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule">Headache</td>
                                 <td styleCode="Lrule Botrule">6%</td>
                                 <td styleCode="Lrule Botrule Rrule">11%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule">Neutropenia</td>
                                 <td styleCode="Lrule Botrule">3%</td>
                                 <td styleCode="Lrule Botrule Rrule">5%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule">Increased alanine aminotransferase</td>
                                 <td styleCode="Lrule Botrule">3%</td>
                                 <td styleCode="Lrule Botrule Rrule">5%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule">Nausea</td>
                                 <td styleCode="Lrule Botrule">3%</td>
                                 <td styleCode="Lrule Botrule Rrule">5%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule">Diarrhea</td>
                                 <td styleCode="Lrule Botrule">0%</td>
                                 <td styleCode="Lrule Botrule Rrule">5%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule">Nasopharyngitis</td>
                                 <td styleCode="Lrule Botrule">0%</td>
                                 <td styleCode="Lrule Botrule Rrule">5%</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Cytokine Release Syndrome (CRS)</content>
                           <br/>  In Study TN-10, CRS was reported in 2% of TZIELD-treated patients compared to 0% of placebo-treated patients.</paragraph>
                        <paragraph>Of the 39 TZIELD-treated patients that developed CRS (5% of all TZIELD-treated patients) in the pool of 5 clinical trials, 13% of the CRS cases were serious adverse reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s5.1">5.1</linkHtml>)]</content>. Liver transaminase elevations were observed in 56% of TZIELD-treated patients who experienced CRS: 64% were up to 2.5 times ULN, 32% were more than 2.5 to 5 times ULN, and 4.5% were 5-10 times ULN.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Serious Infections</content>
                           <br/>  In Study TN-10, serious infections (cellulitis, gastroenteritis, pneumonia, wound infection) were reported in 9% (4/44) of TZIELD-treated patients compared to 0% (0/32) of placebo-treated patients any time during or after the first dose of study treatment.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Rash and Hypersensitivity Reactions</content>
                           <br/>  Hypersensitivity reactions were reported with TZIELD in Study TN-10. Serum sickness was observed in 2% (1/44) of TZIELD-treated patients compared to 0% (0/32) of placebo-treated patients. The patient who developed serum sickness had a prior history of positive anti-nuclear antibody and presented with arthralgias and elevated c-reactive protein and low C4 complement five days after completing their course of TZIELD; illness resolved in 2.5 months.</paragraph>
                        <paragraph>In the pool of 5 clinical trials of patients: <br/>
                           <br/>
                        </paragraph>
                        <list listType="unordered">
                           <item>Anaphylaxis (with hypoxia and bronchospasm) was observed in one TZIELD-treated patient who was hospitalized.</item>
                           <item>Angioedema (periorbital and facial) was observed in 0.3% TZIELD-treated patients, compared to 0% in control-treated patients. Peripheral and generalized edema was reported in 1.6% of TZIELD-treated patients and 0% of control-treated patients.</item>
                           <item>Rash was observed in 48% of TZIELD-treated patients compared to 15% in control-treated patients, with 33 excess cases of rash per 100 patients. The majority of rashes observed with TZIELD treatment were not serious and resolved without intervention; although 0.3% (2/773) of TZIELD-treated patients had a serious rash compared to 0% (0/245) of placebo- treated patients.</item>
                           <item>Urticaria was reported in 1.9% of TZIELD-treated patients and in 1.2% of control-treated patients.</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Immunogenicity: Anti-Drug Antibody-Associated Adverse Reactions</content>
                           <br/>  In Study TN-10, rash occurred in 39% of TZIELD-treated patients who developed anti- teplizumab-mzwv antibodies and in 33% of TZIELD-treated patients who did not develop anti- teplizumab-mzwv antibodies <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s12.6">12.6</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Other Adverse Reactions</content>
                           <br/>
                           <content styleCode="italics">Lymphopenia</content>
                           <br/>  In Study TN-10, lymphopenia was reported in 73% of TZIELD-treated patients compared to 6% of placebo-treated patients. The average lymphocyte count nadir occurred at Day 5 of treatment, with recovery and return to baseline by Week 6 <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s5.3">5.3</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Neutropenia</content>
                           <br/>  In Study TN-10, neutropenia was observed in 7% of TZIELD-treated patients compared to 3% of placebo-treated patients.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Anemia and Thrombocytopenia</content>
                           <br/>  In the pool of 5 clinical trials of patients, anemia was reported in 27% of TZIELD-treated patients compared to 21% of placebo-treated patients, and thrombocytopenia was reported in 13% of TZIELD-treated patients compared to 5% of placebo-treated patients during the 14-day treatment course; recovery occurred within 2 to 4 weeks of treatment. In clinical trials, 1.8% of TZIELD-treated patients discontinued treatment due to hemoglobin less than 8.5 g/dL (or a decrease of more than 2 g/dL to a value less than 10 g/dL), and 1% discontinued TZIELD due to platelet count less than 50,000 platelets/mcL.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Liver Enzyme Elevations</content>
                           <br/>  Liver enzyme elevations were observed in TZIELD-treated patients, both in the context of CRS and in patients without CRS. In the pool of 5 clinical trials, elevated aminotransferases were reported in 25% of TZIELD-treated patients compared to 11% of placebo-treated patients during the 14-day treatment course. On laboratory analysis, 5.1% of TZIELD-treated patients experienced a peak ALT more than 3 times the ULN compared to 0.8% of control-treated patients. Most liver enzyme elevations were transient and resolved 1-2 weeks after treatment; 98% resolved by follow-up week 14.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Other Laboratory Abnormalities</content>
                           <br/>  In the pool of 5 clinical trials, other laboratory abnormalities including decreased bicarbonate (15% in TZIELD-treated patients, compared to 7% in placebo-treated patients) and decreased blood calcium (19% in TZIELD-treated patients, compared to 13% in placebo-treated patients) were noted.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s8">
               <id root="fd7a4d00-adb8-422d-8c8d-34092eebc257"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Pregnancy: May cause fetal harm (<linkHtml href="#s8.1">8.1</linkHtml>).</item>
                           <item>Lactation: A lactating woman may consider pumping and discarding breast milk during and for 20 days after TZIELD administration (<linkHtml href="#s8.2">8.2</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s8.1">
                     <id root="71cd5098-50a4-4013-b8c5-4a9a896ad5dd"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                           <br/>  Available case reports from clinical trials with TZIELD are insufficient to identify a drug- associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. Although there are no data on teplizumab-mzwv, monoclonal antibodies can be actively transported across the placenta, and TZIELD may cause immunosuppression in the utero- exposed infant <content styleCode="italics">(see <linkHtml href="#CC">Clinical Considerations</linkHtml>).</content> To minimize exposure to a fetus, avoid use of TZIELD during pregnancy and at least 30 days (6 half-lives) prior to planned pregnancy.</paragraph>
                        <paragraph>TZIELD is not active in rodents. In animal reproduction studies, mice were given a surrogate anti-mouse CD3 antibody subcutaneously during organogenesis through lactation. Pups born to dams administered the murine surrogate antibody during pregnancy showed a reduction in the adaptive immune response consistent with the expected pharmacology <content styleCode="italics">(see <linkHtml href="#pdata">Data</linkHtml>)</content>.</paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively.</paragraph>
                        <paragraph>Report pregnancies to Provention Bio, Inc.'s Adverse Event reporting line at 1-800-633-1610.</paragraph>
                        <paragraph ID="CC">
                           <content styleCode="underline">Clinical Considerations</content>
                           <br/>
                           <content styleCode="italics">Fetal/Neonatal Adverse Reactions</content>
                           <br/>  Transport of endogenous IgG antibodies across the placenta increases as pregnancy progresses, and peaks during the third trimester. Because teplizumab-mzwv may interfere with immune response to infections, risks and benefits should be considered prior to administering live vaccines to infants exposed to teplizumab-mzwv in utero. There are insufficient data regarding infant serum levels of teplizumab-mzwv at birth and the duration of persistence of teplizumab- mzwv in infant serum after birth to identify a specific timeframe to delay live virus immunizations in infants exposed in utero.</paragraph>
                        <paragraph ID="pdata">
                           <content styleCode="underline">Data</content>
                           <br/>
                           <content styleCode="italics">Animal Data</content>
                           <br/>  In an embryo-fetal developmental toxicity study, pregnant mice were administered a murine surrogate anti-mouse CD3 antibody by subcutaneous injection at dose levels of 0, 0.03, 0.3, or 20 mg/kg on Gestation Days 6, 10, and 14. Increase in post-implantation loss occurred in the 20 mg/kg group, in the presence of maternal toxicity.</paragraph>
                        <paragraph>In a pre- and postnatal development toxicity study in pregnant mice, in which the murine surrogate antibody was administered every 3 days from gestation day 6 through lactation day 19 at doses of 0, 0.3, 3, or 20 mg/kg, no maternal toxicity or increased incidence of post- implantation loss was observed. Reductions in T cell populations and increases in B cells, and a reduction in the adaptive immune response to keyhole limpet hemocyanin (KLH) were observed in the offspring on postnatal days 35 and 84 at 20 mg/kg. The surrogate antibody was present in the offspring serum at level less than 1.5% that of maternal serum at the high dose. A trend towards reduction in fertility was observed in the offspring of dams administered the murine surrogate antibody at 20 mg/kg. The human relevance of this finding is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="s8.2">
                     <id root="61471b99-49e1-4d46-ac0b-f4622bf99ddd"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                           <br/>  There are no data on the presence of teplizumab-mzwv in either human or animal milk, the effects on the breastfed child, or the effects on milk production. Endogenous maternal IgG and monoclonal antibodies are transferred into human milk. The effects of local gastrointestinal exposure and limited systemic exposure in the breastfed infant to teplizumab-mzwv are unknown.</paragraph>
                        <paragraph>Although the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for TZIELD and any potential adverse effects on the breastfed child from TZIELD or from the underlying maternal condition, a lactating woman may interrupt breastfeeding and pump and discard breast milk during treatment and for 20 days after TZIELD administration to minimize drug exposure to a breastfed child.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="s8.4">
                     <id root="ed7c450d-3ef0-4bae-a871-a03a5bf2d1f0"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of TZIELD to delay the onset of Stage 3 type 1 diabetes have been established in pediatric patients 8 years of age and older with Stage 2 type 1 diabetes. Use of TZIELD for this indication is supported by evidence from an adequate and well-controlled study (Study TN-10) in adults and pediatric patients 8 years of age and older (including 29 pediatric patients). Adverse reactions observed in pediatric patients 8 years of age and older who received TZIELD were consistent with those reported in adult patients <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s6.1">6.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>The safety and effectiveness of TZIELD have not been established in pediatric patients younger than 8 years of age.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="s8.5">
                     <id root="510c7388-8561-4df4-b616-076277a694b5"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Stage 2 type 1 diabetes is largely a condition that occurs in pediatric and younger adult patients. Clinical studies of TZIELD to delay the onset of Stage 3 T1D did not include patients 65 years of age and older.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s11">
               <id root="cb4e4a89-04bc-4f3c-89c3-d85c95b710db"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Teplizumab-mzwv is a CD3-directed monoclonal antibody (humanized IgG1 kappa) that has a molecular weight of approximately 150 kilodalton (kDa) and is expressed from a recombinant Chinese hamster ovary (CHO) cell line.</paragraph>
                  <paragraph>TZIELD (teplizumab-mzwv) injection is supplied as a sterile, preservative-free, clear and colorless solution in a 2 mg/2 mL (1 mg/mL) single-dose vial for intravenous use. Each mL contains 1 mg of teplizumab-mzwv, dibasic sodium phosphate (0.26 mg), monobasic sodium phosphate (0.98 mg), polysorbate 80 (0.05 mg), sodium chloride (8.78 mg), and water for injection. The pH is 6.1.</paragraph>
               </text>
               <effectiveTime value="20250430"/>
            </section>
         </component>
         <component>
            <section ID="s12">
               <id root="ec236638-ab77-47ff-90a4-22b823e11998"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250430"/>
               <component>
                  <section ID="s12.1">
                     <id root="4e42d387-bcf9-4c98-b4e9-1e5a4edf5c3e"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Teplizumab-mzwv binds to CD3 (a cell surface antigen present on T lymphocytes) and delays the onset of Stage 3 type 1 diabetes in adults and pediatric patients aged 8 years and older with Stage 2 type 1 diabetes. The mechanism may involve partial agonistic signaling and deactivation of pancreatic beta cell autoreactive T lymphocytes. Teplizumab-mzwv leads to an increase in the proportion of regulatory T cells and of exhausted CD8+ T cells in peripheral blood.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="s12.2">
                     <id root="ff183577-0e88-4348-b315-2e33be8008f5"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Clinical studies have shown that teplizumab-mzwv binds to CD3 molecules on the surface of both CD4+ and CD8+ T cells during treatment, with internalization of the teplizumab- mzwv/CD3 complex from the surface of T cells. Pharmacodynamic effects include lymphopenia in the absence of depletion of T cells with a nadir on the 5th day of dosing, during a 14-day course of TZIELD treatment <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s5.3">5.3</linkHtml>)]</content>. Teplizumab-mzwv exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of teplizumab-mzwv have not been fully characterized.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="s12.3">
                     <id root="e6961fb4-b59d-4e04-ab3f-2ed63e0dee55"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Steady state concentrations of teplizumab-mzwv are not expected to be achieved during the 14- day course of TZIELD.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                           <br/>  The central volume of distribution (Vd) of teplizumab-mzwv was 2.27 L in a 60 kg subject.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                           <br/>  Teplizumab-mzwv showed saturable binding and elimination. The mean (SD) terminal elimination half-life and clearance of teplizumab-mzwv are 4.5 (0.2) days and 2.7 (0.8) L/day in a 60 kg subject, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Metabolism</content>
                           <br/>  Teplizumab-mzwv is expected to be metabolized into small peptides by catabolic pathways.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                           <br/>  No clinically significant differences in the pharmacokinetics of teplizumab-mzwv were observed based on age (8 to 35 years old), biologic sex, or racial groups (White, Asians).</paragraph>
                        <paragraph>BSA-based dosing normalizes the exposure to teplizumab-mzwv across body weight.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="s12.6">
                     <id root="c7d6a774-e7bf-40cb-9462-0645c58b802a"/>
                     <code code="88830-5" codeSystem="2.16.840.1.113883.6.1" displayName="IMMUNOGENICITY"/>
                     <title>12.6 Immunogenicity</title>
                     <text>
                        <paragraph>The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of teplizumab-mzwv or of other teplizumab products.</paragraph>
                        <paragraph>In the placebo-controlled study in patients aged 8 years of age and older with Stage 2 type 1 diabetes (Study TN-10) <content styleCode="italics">[see Clinical Studies (<linkHtml href="#s14">14</linkHtml>)]</content>, approximately 57% of TZIELD-treated patients developed anti-teplizumab-mzwv antibodies, 46% of whom developed neutralizing antibodies. There is insufficient information to characterize the effects of ADA on pharmacokinetics, pharmacodynamics, or effectiveness of TZIELD. There was a higher incidence of rash in TZIELD-treated patients who developed anti-teplizumab-mzwv antibodies compared to those who did not develop anti-teplizumab-mzwv antibodies <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s6.1">6.1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s13">
               <id root="085f2e9d-4018-4291-8ad5-c6e4ebaa7bdd"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250430"/>
               <component>
                  <section ID="s13.1">
                     <id root="5634d8c3-e389-4187-a9d1-556c3bc6fffc"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>No long-term studies have been performed to assess the carcinogenic potential of teplizumab- mzwv.</paragraph>
                        <paragraph>No studies have been performed to assess the mutagenic potential of teplizumab-mzwv. As an antibody, teplizumab-mzwv is not expected to interact directly with DNA.</paragraph>
                        <paragraph>Fertility and reproductive performance were unaffected in female and male mice that received a murine surrogate anti-mouse CD3 antibody administered by the subcutaneous route at doses up to 20 mg/kg.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s14">
               <id root="3a4f6ff5-519e-45fb-9046-2d259dc6e8de"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>The effectiveness of TZIELD was investigated in a randomized, double-blind, event-driven, placebo-controlled study (Study TN-10; NCT01030861) in 76 patients, 8 to 49 years of age with Stage 2 type 1 diabetes. Stage 2 type 1 diabetes was defined as having both of the following: <br/>
                     <br/>
                  </paragraph>
                  <list listType="ordered">
                     <item>Two or more of the following pancreatic islet autoantibodies:<list listType="unordered">
                           <item>Glutamic acid decarboxylase 65 (GAD) autoantibodies</item>
                           <item>Insulin autoantibody (IAA)</item>
                           <item>Insulinoma-associated antigen 2 autoantibody (IA-2A)</item>
                           <item>Zinc transporter 8 autoantibody (ZnT8A)</item>
                           <item>Islet cell autoantibody (ICA)</item>
                        </list>
                        <br/>
                     </item>
                     <item>Dysglycemia on oral glucose tolerance testing</item>
                  </list>
                  <paragraph>In this study, patients were randomized to receive TZIELD or placebo once daily by intravenous infusion for 14 days. Patients in the TZIELD group had a total drug exposure that was comparable to the total drug exposure achieved with the recommended total TZIELD dosage <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s2.4">2.4</linkHtml>)]</content>. The primary efficacy endpoint in this study was the time from randomization to development of Stage 3 type 1 diabetes diagnosis.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Baseline Patient Characteristics</content>
                     <br/>  In this study, 45% were female; 97% White, 1% Asian, and 1% reported multiracial background; 3% were Hispanic or Latino ethnicity; and 95% were from the United States. The median age was 14 years (72% were &lt;18 years old) (<linkHtml href="#t2">Table 2</linkHtml>).</paragraph>
                  <table width="95%" ID="t2">
                     <caption>Table 2. Baseline Age Characteristics of Adults and Pediatric Patients 8 Years of Age and Older with Stage 2 Type 1 Diabetes (Study TN-10)<footnote ID="table_2_footnote1">Intent to treat (ITT) population</footnote>
                     </caption>
                     <col width="40%" align="left" valign="middle"/>
                     <col width="30%" align="center" valign="middle"/>
                     <col width="30%" align="center" valign="middle"/>
                     <thead>
                        <tr>
                           <th styleCode="Lrule Botrule" valign="top"/>
                           <th styleCode="Lrule Botrule">TZIELD <br/>  N=44</th>
                           <th styleCode="Lrule Botrule Rrule">Placebo <br/>  N=32</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule Botrule">
                              <content styleCode="bold">Age Group</content>
                           </td>
                           <td styleCode="Botrule"/>
                           <td styleCode="Botrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">≥ 18 Years</td>
                           <td styleCode="Lrule Botrule">34%</td>
                           <td styleCode="Lrule Botrule Rrule">19%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">&lt; 18 years</td>
                           <td styleCode="Lrule Botrule">66%</td>
                           <td styleCode="Lrule Botrule Rrule">81%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">
                              <content styleCode="bold">Pediatric Age Group Quartiles</content>
                           </td>
                           <td styleCode="Botrule"/>
                           <td styleCode="Botrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">8 to &lt;11 years</td>
                           <td styleCode="Lrule Botrule">21%</td>
                           <td styleCode="Lrule Botrule Rrule">25%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">11 to &lt;14 years</td>
                           <td styleCode="Lrule Botrule">27%</td>
                           <td styleCode="Lrule Botrule Rrule">31%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">14 to &lt;18 years</td>
                           <td styleCode="Lrule Botrule">18%</td>
                           <td styleCode="Lrule Botrule Rrule">25%</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="underline">Baseline Disease Characteristics</content>
                     <br/>
                     <linkHtml href="#t3">Table 3</linkHtml> displays the baseline disease characteristics in Study TN-10.</paragraph>
                  <table width="95%" ID="t3">
                     <caption>Table 3. Baseline Disease Characteristics of Adults and Pediatric Patients 8 Years of Age and Older with Stage 2 Type 1 Diabetes (Study TN-10)<footnote ID="table_3_footnote1">Intent to treat (ITT) population</footnote>
                     </caption>
                     <col width="40%" align="left" valign="middle"/>
                     <col width="30%" align="center" valign="middle"/>
                     <col width="30%" align="center" valign="middle"/>
                     <thead>
                        <tr>
                           <th styleCode="Lrule Botrule" valign="top"/>
                           <th styleCode="Lrule Botrule">TZIELD <br/>  N=44</th>
                           <th styleCode="Lrule Botrule Rrule">Placebo <br/>  N=32</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule Botrule">
                              <content styleCode="bold">Glucose, mg/dL<footnote ID="table_3_footnote2">The glucose data are area under the time-concentration curve (AUC) values from the oral glucose tolerance test</footnote>
                              </content>
                           </td>
                           <td styleCode="Botrule"/>
                           <td styleCode="Botrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">median (min, max)</td>
                           <td styleCode="Lrule Botrule">165 (115, 207)</td>
                           <td styleCode="Lrule Botrule Rrule">154 (103, 200)</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">
                              <content styleCode="bold">HbA1c, %</content>
                           </td>
                           <td styleCode="Botrule"/>
                           <td styleCode="Botrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">median (min, max)</td>
                           <td styleCode="Lrule Botrule">5.2 (4.6, 6.1)</td>
                           <td styleCode="Lrule Botrule Rrule">5.3 (4.3, 5.6)</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">
                              <content styleCode="bold">HLA-DR4</content>
                           </td>
                           <td styleCode="Botrule"/>
                           <td styleCode="Botrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">Missing</td>
                           <td styleCode="Lrule Botrule">5%</td>
                           <td styleCode="Lrule Botrule Rrule">0</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">Absent</td>
                           <td styleCode="Lrule Botrule">34%</td>
                           <td styleCode="Lrule Botrule Rrule">34%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">Present</td>
                           <td styleCode="Lrule Botrule">61%</td>
                           <td styleCode="Lrule Botrule Rrule">66%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">
                              <content styleCode="bold">HLA-DR3</content>
                           </td>
                           <td styleCode="Botrule"/>
                           <td styleCode="Botrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">Missing</td>
                           <td styleCode="Lrule Botrule">5%</td>
                           <td styleCode="Lrule Botrule Rrule">0</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">Absent</td>
                           <td styleCode="Lrule Botrule">48%</td>
                           <td styleCode="Lrule Botrule Rrule">53%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">Present</td>
                           <td styleCode="Lrule Botrule">48%</td>
                           <td styleCode="Lrule Botrule Rrule">47%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">
                              <content styleCode="bold">HLA-DR3/DR4</content>
                           </td>
                           <td styleCode="Botrule"/>
                           <td styleCode="Botrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">Both DR3 and DR4</td>
                           <td styleCode="Lrule Botrule">25%</td>
                           <td styleCode="Lrule Botrule Rrule">22%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">DR3 only</td>
                           <td styleCode="Lrule Botrule">23%</td>
                           <td styleCode="Lrule Botrule Rrule">25%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">DR4 only</td>
                           <td styleCode="Lrule Botrule">36%</td>
                           <td styleCode="Lrule Botrule Rrule">44%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">Missing</td>
                           <td styleCode="Lrule Botrule">5%</td>
                           <td styleCode="Lrule Botrule Rrule">0</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">Neither DR3 nor DR4</td>
                           <td styleCode="Lrule Botrule">11%</td>
                           <td styleCode="Lrule Botrule Rrule">9%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">
                              <content styleCode="bold">Autoantibodies Positive (N)</content>
                           </td>
                           <td styleCode="Botrule"/>
                           <td styleCode="Botrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">1</td>
                           <td styleCode="Lrule Botrule">2%</td>
                           <td styleCode="Lrule Botrule Rrule">0</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">2</td>
                           <td styleCode="Lrule Botrule">27%</td>
                           <td styleCode="Lrule Botrule Rrule">22%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">3</td>
                           <td styleCode="Lrule Botrule">25%</td>
                           <td styleCode="Lrule Botrule Rrule">16%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">4</td>
                           <td styleCode="Lrule Botrule">27%</td>
                           <td styleCode="Lrule Botrule Rrule">44%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">5</td>
                           <td styleCode="Lrule Botrule">18%</td>
                           <td styleCode="Lrule Botrule Rrule">19%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">
                              <content styleCode="bold">Autoantibody Type Positive</content>
                           </td>
                           <td styleCode="Botrule"/>
                           <td styleCode="Botrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">GAD65</td>
                           <td styleCode="Lrule Botrule">91%</td>
                           <td styleCode="Lrule Botrule Rrule">88%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">IAA</td>
                           <td styleCode="Lrule Botrule">43%</td>
                           <td styleCode="Lrule Botrule Rrule">34%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">IA-2A</td>
                           <td styleCode="Lrule Botrule">59%</td>
                           <td styleCode="Lrule Botrule Rrule">75%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">ICA</td>
                           <td styleCode="Lrule Botrule">66%</td>
                           <td styleCode="Lrule Botrule Rrule">88%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">ZnT8</td>
                           <td styleCode="Lrule Botrule">73%</td>
                           <td styleCode="Lrule Botrule Rrule">75%</td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode="Lrule Botrule Rrule">
                              <sub>Abbreviations: HbA1c=hemoglobin A1c, SD=standard deviation, HLA = human leukocyte antigen, GAD65=Glutamic acid decarboxylase 65 (GAD) autoantibodies, IAA=Insulin autoantibody, IA- 2A=Insulinoma-associated antigen 2 autoantibody, ZnT8A=Zinc transporter 8 autoantibody, ICA=Islet cell autoantibody</sub>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="underline">Efficacy Results</content>
                     <br/>  In Study TN-10, Stage 3 type 1 diabetes was diagnosed in 20 (45%) of the TZIELD-treated patients and in 23 (72%) of the placebo-treated patients. A Cox proportional hazards model, stratified by age and oral glucose tolerance test status at randomization, demonstrated that the median time from randomization to Stage 3 type 1 diabetes diagnosis was 50 months in the TZIELD group and 25 months in the placebo group, for a difference of 25 months. With a median follow-up time of 51 months, therapy with TZIELD resulted in a statistically significant delay in the development of Stage 3 type 1 diabetes, hazard ratio 0.41 (95% CI: 0.22 to 0.78; p=0.0066) (<linkHtml href="#f1">Figure 1</linkHtml>).</paragraph>
                  <paragraph>Study TN-10 was not designed to assess whether there were differences in the effectiveness between subgroups based on demographic characteristics or baseline disease characteristics.</paragraph>
                  <paragraph ID="f1">
                     <content styleCode="bold">Figure 1: Kaplan-Meier Curve of Time to Diagnosis of Stage 3 Type 1 Diabetes in Adult and Pediatric Patients Aged 8 Years and Older with Stage 2 Type 1 Diabetes by Treatment Group (Study TN-10)</content>
                     <footnote ID="K2230">ITT population</footnote>
                  </paragraph>
                  <renderMultiMedia ID="m1" referencedObject="figure-01"/>
               </text>
               <effectiveTime value="20250430"/>
               <component>
                  <observationMedia ID="figure-01">
                     <text>Image of Figure 1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="e8a39a5f-139c-4510-9777-71cbb00138fa-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s16">
               <id root="15dd3459-57ca-452c-aec0-11ef2e18c8d9"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED / STORAGE AND HANDLING</title>
               <text>
                  <paragraph>TZIELD (teplizumab-mzwv) injection is a clear and colorless solution (2 mg/2 mL (1 mg/mL)) supplied in a single-dose vial as follows:</paragraph>
                  <table width="50%" ID="t4">
                     <col width="50%" align="left" valign="middle"/>
                     <col width="50%" align="left" valign="middle"/>
                     <thead>
                        <tr>
                           <th styleCode="Lrule Botrule">Carton Contents</th>
                           <th styleCode="Lrule Botrule Rrule">NDC</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule Botrule">1 single dose vial</td>
                           <td styleCode="Lrule Botrule Rrule">NDC 73650-316-01</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">10 single dose vials</td>
                           <td styleCode="Lrule Botrule Rrule">NDC 73650-316-10</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule">14 single dose vials</td>
                           <td styleCode="Lrule Botrule Rrule">NDC 73650-316-14</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Refrigerate TZIELD vials at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Store upright. Do not freeze or shake the vials.</paragraph>
                  <paragraph>If not used immediately, store the diluted solution at room temperature [15°C to 30°C (59°F to 86°F)] and complete infusion within 4 hours of the start of preparation. Discard the diluted solution if not administered within 4 hours of preparation <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s2.5">2.5</linkHtml>)]</content>.</paragraph>
               </text>
               <effectiveTime value="20250430"/>
            </section>
         </component>
         <component>
            <section ID="s17">
               <id root="b1fc85cc-de98-4e4c-b2c4-5fc26c089a8e"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (<linkHtml href="#smedgde">Medication Guide</linkHtml>).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Cytokine Release Syndrome</content>
                     <br/>  Inform patients about the signs and symptoms of CRS <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s5.1">5.1</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Serious Infections</content>
                     <br/>  Inform patients that TZIELD may lower the ability of the immune system to fight infections. Instruct patients to contact their health care provider if they develop any symptoms of infection <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s5.2">5.2</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Lymphopenia</content>
                     <br/>  Inform patients that although most TZIELD-treated patients had mild lymphopenia; a few had severe lymphopenia that required stopping TZIELD <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s5.3">5.3</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Hypersensitivity Reactions</content>
                     <br/>  Advise patients on the symptoms of hypersensitivity reactions and instruct them to stop taking TZIELD and seek medical attention promptly if such symptoms occur <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s5.4">5.4</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Vaccinations</content>
                     <br/>  Advise patient to receive all age-appropriate vaccinations prior to starting TZIELD and avoid concurrent use of live, inactivated, and mRNA vaccines with TZIELD <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s5.5">5.5</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Pregnancy</content>
                     <br/>  Advise patients to inform their health care provider of a known or suspected pregnancy. Advise patients who are exposed to TZIELD during pregnancy to contact Provention Bio, Inc.'s Adverse Event reporting line at 1-800-633-1610 <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s8.1">8.1</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Lactation</content>
                     <br/>  Advise a lactating woman that she may interrupt breastfeeding and pump and discard breast milk during treatment and for 20 days after TZIELD administration to minimize drug exposure to a breastfed infant <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s8.2">8.2</linkHtml>)]</content>.</paragraph>
                  <paragraph>Manufactured by: <br/>  Provention Bio, Inc. <br/>  Morristown, NJ 07960<br/> A SANOFI COMPANY</paragraph>
                  <br/>
                  <paragraph>U.S. License Number: 2170 <br/>  TZIELD is a registered trademark of Provention Bio, Inc. <br/>  Copyright © 2025, Provention Bio, Inc. All rights reserved.</paragraph>
               </text>
               <effectiveTime value="20250430"/>
            </section>
         </component>
         <component>
            <section ID="smedgde">
               <id root="4b6a0657-47ed-40b1-aaab-a7827d42f6cf"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <table ID="table-ppi1" width="100%">
                     <col width="75%" align="left" valign="top"/>
                     <col width="25%" align="right" valign="bottom"/>
                     <tbody>
                        <tr>
                           <td colspan="2" align="center" styleCode="Lrule Rrule Botrule">
                              <content styleCode="bold">MEDICATION GUIDE <br/>  TZIELD<sup>®</sup> (TEE-zeeld) <br/>  (teplizumab-mzwv) <br/>  injection, for intravenous use</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Lrule Rrule Botrule">
                              <content styleCode="bold">What is the most important information I should know about TZIELD?</content>
                              <br/>
                              <br/>
                              <content styleCode="bold">TZIELD may cause serious side effects, including:</content>
                              <br/>
                              <br/>
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">Cytokine Release Syndrome (CRS).</content> Signs and symptoms of CRS problems may include:<list listType="unordered">
                                       <item>fever</item>
                                       <item>feeling tired (fatigue)</item>
                                       <item>muscle and joint pain</item>
                                       <item>nausea</item>
                                       <item>headache</item>
                                       <item>increased liver enzymes in your blood</item>
                                    </list>These signs and symptoms may start during the first 5 days of TZIELD treatment. Tell your healthcare provider right away if you develop any signs and symptoms of CRS during treatment with TZIELD.</item>
                                 <item>
                                    <content styleCode="bold">Decrease in white blood cells.</content> TZIELD may cause a decrease in a type of white blood cell called lymphocytes. A decrease in white blood cells is a serious, but common side effect that can affect your body's ability to fight infections. A decrease in white blood cell counts can happen after your first dose. Your white blood cell counts will start to go back to normal after your fifth dose of TZIELD. Some people may develop longer and more severe decreases in lymphocytes.</item>
                              </list>Your healthcare provider will do blood tests to check your liver and your complete blood counts before you start treatment and during treatment with TZIELD. During and after your treatment with TZIELD, your healthcare provider will check for serious side effects, as well as other side effects, and treat you as needed. Your healthcare provider may temporarily or completely stop your treatment with TZIELD, if you develop liver problems, have a serious infection, or if your blood counts stay too low. <br/>
                              <br/>See <content styleCode="bold">"What are the possible side effects of TZIELD?"</content> for more information about side effects.</td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Lrule Rrule Botrule">
                              <content styleCode="bold">What is TZIELD?</content>
                              <br/>
                              <br/>  TZIELD is a prescription medicine used to delay the onset of Stage 3 type 1 diabetes, which is when your body can't make enough insulin on its own and may require insulin injections. TZIELD is for adults and children 8 years of age and older who have Stage 2 type 1 diabetes. This means that they have tested positive for 2 or more type 1 diabetes-related autoantibodies, have abnormal blood sugar levels and do not have type 2 diabetes. <br/>  It is not known if TZIELD is safe and effective in children under 8 years of age.</td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Lrule Rrule Botrule">
                              <content styleCode="bold">Before or after receiving TZIELD, tell your healthcare provider about all your medical conditions, including if you:</content>
                              <list listType="unordered">
                                 <item>have any of the conditions or symptoms listed in the section <content styleCode="bold">"What is the most important information I should know about TZIELD?"</content>
                                 </item>
                                 <item>have a serious infection or an infection that does not go away or that keeps coming back (chronic).</item>
                                 <item>have recently received or are scheduled to receive an immunization (vaccine). TZIELD may affect how well a vaccine works. Tell your healthcare provider that you are receiving treatment with TZIELD before receiving a vaccine.</item>
                                 <item>are pregnant or plan to become pregnant. TZIELD may harm your unborn baby. <content styleCode="bold">Do not</content> receive TZIELD during pregnancy and at least 30 days before a planned pregnancy.</item>
                                 <item>If you become pregnant while taking TZIELD, you are encouraged to report your pregnancy to the Provention Bio's Adverse Event reporting line at 1-800-633-1610.</item>
                                 <item>are breastfeeding or plan to breast feed. It is not known if TZIELD passes into your breast milk and if it can harm your baby. Talk to your healthcare provider about the best way to feed your baby if you receive TZIELD. If you are breastfeeding, you may consider pumping and throwing away your breast milk during treatment with TZIELD and for 20 days after receiving TZIELD treatment.</item>
                              </list>
                              <content styleCode="bold">Tell your healthcare provider about all the medicines you take</content>, including prescription and over-the-counter medicines, vitamins, and herbal supplements.</td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Lrule Rrule Botrule">
                              <content styleCode="bold">How will I receive TZIELD?</content>
                              <br/>
                              <br/>
                              <list listType="unordered">
                                 <item>TZIELD is given by a healthcare provider through a needle placed in a vein (intravenous infusion) in your arm.</item>
                                 <item>You will receive a TZIELD infusion one-time a day, every day, for 14 days. Each TZIELD infusion will last about 30 minutes.</item>
                                 <item>For the first 5 days of treatment, your healthcare provider will give you medicines by mouth before starting your TZIELD infusion. These medicines include ibuprofen, naproxen or other pain relievers such as acetaminophen, an antihistamine, and an anti-nausea medicine. These medicines may help reduce symptoms of CRS such as a fever, headache, muscle and joint pain, or nausea.</item>
                                 <item>If you miss a scheduled infusion, your healthcare provider will continue your treatment on the next scheduled day. You will not receive 2 infusions on the same day.</item>
                              </list>
                              <content styleCode="bold">Tell your healthcare provider if you think something will stop you from completing treatment with TZIELD.</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Lrule Rrule Botrule">
                              <content styleCode="bold">What are the possible side effects of TZIELD? <br/>
                                 <br/>  TZIELD may cause serious side effects including:</content>
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">See </content> "<content styleCode="bold">What is the most important information I should know about TZIELD?</content>"</item>
                              </list>
                              <content styleCode="bold">The most common side effects of TZIELD include:</content>
                              <list listType="unordered">
                                 <item>rash</item>
                                 <item>leukopenia (decrease in white blood cell counts)</item>
                                 <item>headache</item>
                              </list>These are not all of the possible side effects of TZIELD. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Provention Bio at 1-800-633-1610.</td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Lrule Rrule Botrule">
                              <content styleCode="bold">General information about the safe and effective use of TZIELD.</content>
                              <br/>
                              <br/>  Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your pharmacist or healthcare provider for information about TZIELD that is written for health professionals.</td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">What are the ingredients in TZIELD? <br/>  Active ingredient:</content> teplizumab-mzwv. <br/>
                              <content styleCode="bold">Inactive ingredients:</content> dibasic sodium phosphate, monobasic sodium phosphate, polysorbate 80, sodium chloride, and water for injection.</td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Lrule Rrule Botrule">Manufactured by: <br/>  Provention Bio, Inc. <br/>  Morristown, NJ 07960 <br/>A SANOFI COMPANY<br/>
                              <br/>  U.S. License Number: 2170 <br/>
                              <br/>  TZIELD is a registered trademark of Provention Bio, Inc. <br/>
                              <br/>  Copyright © 2025, Provention Bio, Inc. All rights reserved. <br/>
                              <br/>  For more information, call 1-800-633-1610 or go to www.tzield.com.</td>
                        </tr>
                        <tr>
                           <td>
                              <sub>This Medication Guide has been approved by the U.S. Food and Drug Administration.</sub>
                           </td>
                           <td>
                              <sub>Issued: 04/2025</sub>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250430"/>
            </section>
         </component>
         <component>
            <section ID="p1">
               <id root="080133eb-5f51-4717-b835-29509b78f4d8"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <br/>
                     <content styleCode="bold">Package Label - 1 count - 2 mg/2 mL Single-use Vial</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
                     <br/>
                     <br/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 73650-316-01</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Tzield™</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(teplizumab-mzwv)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">INJECTION</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">2 mg/2 mL (1 mg/1 mL)</content>
                  </paragraph>
                  <paragraph>Contains 1 single dose vial. <br/>  Discard unused portion.</paragraph>
                  <paragraph>
                     <content styleCode="bold">For intravenous infusion after dilution.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Store in the original carton <br/>  to protect from light.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Dispense the accompanying <br/>  Medication Guide to each patient.</content>
                  </paragraph>
                  <paragraph>proventionbio</paragraph>
                  <renderMultiMedia ID="m2" referencedObject="princ-panel-carton-1"/>
               </text>
               <effectiveTime value="20250430"/>
               <component>
                  <observationMedia ID="princ-panel-carton-1">
                     <text>Image of Carton - Principal Panel - 1 count - 2 mg/2 mL Single-use Vial</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="e8a39a5f-139c-4510-9777-71cbb00138fa-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="p2">
               <id root="34b3e37c-c5d6-40c5-9ed9-136caf025ae0"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <br/>
                     <content styleCode="bold">Package Label - 10 count - 2 mg/2 mL Single-use Vial</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
                     <br/>
                     <br/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 73650-316-10</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Tzield™</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(teplizumab-mzwv)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">INJECTION</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">2 mg/2 mL (1 mg/1 mL)</content>
                  </paragraph>
                  <paragraph>Contains 10 single dose vials. <br/>  Discard unused portion.</paragraph>
                  <paragraph>
                     <content styleCode="bold">For intravenous infusion after dilution.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Store in the original carton to protect <br/>  from light.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Dispense the accompanying <br/>  Medication Guide to each patient.</content>
                  </paragraph>
                  <paragraph>proventionbio</paragraph>
                  <renderMultiMedia ID="m3" referencedObject="princ-panel-carton-2"/>
               </text>
               <effectiveTime value="20250430"/>
               <component>
                  <observationMedia ID="princ-panel-carton-2">
                     <text>Image of Carton - Principal Panel - 10 count - 2 mg/2 mL Single-use Vial</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="e8a39a5f-139c-4510-9777-71cbb00138fa-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="p3">
               <id root="0f27b541-03d1-4a10-9e0b-83324c4c6c57"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <br/>
                     <content styleCode="bold">Package Label - 14 count - 2 mg/2 mL Single-use Vial</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
                     <br/>
                     <br/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 73650-316-14</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Tzield™</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(teplizumab-mzwv)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">INJECTION</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">2 mg/2 mL (1 mg/1 mL)</content>
                  </paragraph>
                  <paragraph>Contains 14 single dose vials. <br/>  Discard unused portion.</paragraph>
                  <paragraph>
                     <content styleCode="bold">For intravenous infusion after dilution.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Store in the original carton to protect <br/>  from light.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Dispense the accompanying <br/>  Medication Guide to each patient.</content>
                  </paragraph>
                  <paragraph>proventionbio</paragraph>
                  <renderMultiMedia ID="m4" referencedObject="princ-panel-carton-3"/>
               </text>
               <effectiveTime value="20250430"/>
               <component>
                  <observationMedia ID="princ-panel-carton-3">
                     <text>Image of Carton - Principal Panel - 14 count - 2 mg/2 mL Single-use Vial</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="e8a39a5f-139c-4510-9777-71cbb00138fa-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>